Pay in 4 interest-free payments of $6.38 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
[1] The pivotal SURPASS trials, which evaluated tirzepatide in over 6,000 patients with type 2 diabetes, did not identify pharyngitis or throat pain as a significant treatment-related adverse event
Medical Safety Issues Using retatrutide without medical supervision means: No monitoring for side effects or complications Inappropriate dosing without medical guidance Drug interactions that go undetected Emergency situations without proper medical support FDA-Approved Alternatives to Consider While waiting for potential retatrutide approval, several FDA-approved weight loss medications are available through legitimate medical channels: GLP-1 Receptor Agonists These medications work similarly to one component of retatrutides triple action: Semaglutide (Ozempic for diabetes and Wegovy for weight loss) Tirzepatide (GLP-1/GIP receptor agonist sold as Mounjaro for diabetes and Zepbound for weight loss) Liraglutide (Victoza for diabetes and Saxenda for weight loss) Orforglipron (Foundayo) Other Prescription Options Additional FDA-approved weight loss medications include: These medications require prescriptions from licensed healthcare providers who can properly evaluate your eligibility and monitor your progress
Lam CSP, Brutsaert DL
May 28, 2026
US$ 27.03
US$ 25.69
US$ 24.74
